Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature
DOI: https://doi.org/10.2147/IJN.S377816
IF: 7.033
2022-09-16
International Journal of Nanomedicine
Abstract:Mingxin Cao, 1, &ast Enyu Shi, 1, &ast Hanping Wang, 1 Lujia Mao, 1 Qiqi Wu, 1 Xinming Li, 2 Yanjie Liang, 1 Xiaoying Yang, 3 Yinsong Wang, 1, 3 Changyi Li 1 1 School and Hospital of Stomatology, Tianjin Medical University, Tianjin, 300070, People's Republic of China; 2 Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Tianjin, 300041, People's Republic of China; 3 Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yinsong Wang; Changyi Li, Email ; Oral squamous cell carcinoma (OSCC) is the most common type of malignant tumor in the head and neck, with a poor prognosis mainly due to recurrence and metastasis. Classical treatment modalities for OSCC like surgery and radiotherapy have difficulties in dealing with metastatic tumors, and together with chemotherapy, they have major problems related to non-specific cell death. Molecular targeted therapies offer solutions to these problems through not only potentially maximizing the anticancer efficacy but also minimizing the treatment-related toxicity. Among them, the receptor-mediated targeted delivery of anticancer therapeutics remains the most promising one. As OSCC exhibits a heterogeneous nature, selecting the appropriate receptors for targeting is the prerequisite. Hence, we reviewed the OSCC-associated receptors previously used in targeted therapy, focused on their biochemical characteristics and expression patterns, and discussed the application potential in personalized targeted therapy of OSCC. We hope that a better comprehension of this subject will help to provide the fundamental information for OSCC personalized therapeutic planning. Keywords: oral squamous cell carcinoma, receptors, targeted therapy, active targeting, drug delivery Oral squamous cell carcinoma (OSCC), originating from the mucosa of the tongue, buccal, palate, floor of the mouth, alveolar ridge, and other parts of the oral cavity, is the most common malignant tumor in the head and neck. The newest global cancer statistics reported that OSCC accounted for over 370,000 new cancers and 170,000 cases of death. 1 Despite lots of efforts having been put on treatment of OSCC, its five-year survival rate is still no more than 50%. The leading causes for poor prognosis might be correlated to recurrence and metastasis, which could be due to incomplete resection of tumor and neglected metastases. 2,3 Developing more efficient therapeutics is essential for improving prognosis of OSCC. The principal strategies for OSCC treatment are surgery, chemotherapy, radiotherapy, or a combination of these modalities based on the severity of disease. 4,5 Surgery remains the most efficient treatment for OSCC, while it inevitably damages the functions and aesthetics of the orofacial region. 6 Moreover, together with radiotherapy, they have difficulties in dealing with metastatic tumors. 7 Chemotherapy could inhibit rapidly growing cells including those in metastatic sites via inhibiting cell growth and division. 8,9 However, its selective toxicity is relatively low, and normal cells with enhanced proliferation rates such as the hair follicles, bone marrow and gastrointestinal tract could also be harmed. 10 To alleviate toxicities to normal cells, chemotherapeutics is often used at suboptimal doses, which might lead to the final failure of treatment, and even drug resistance and metastatic disease. Therefore, there has been a great pursuit for development of targeted anticancer drugs to increase the selective toxicity in cancer therapy. At present, two targeted approaches are being explored for improving the selective toxicity. One is developing newer drugs that alter specific signaling pathways of cancer cells. 11,12 For example, bevacizumab, a monoclonal antibody that directly targets vascular endothelial growth factor receptor (VEGFR), suppresses functions of all VEGF-A isoforms and blocks correlated downstream signaling, leading to cell-cycle arrest, apoptosis and anti-angiogenesis. 13 However, researches for these molecular targeted therapies will not be pressed ahead further, as these may cause a series of adverse effects in normal cells that usually distinct from classical cytotoxic chemotherapy. 14 The other emerging one is targeted delivery of anticancer drugs to cancer region, increasing the drug dosages that reach t -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology